In this video series, three experts present the most important changes in the ESC/EAS dyslipidemia guidelines, lessons learned after 5 years of use with PCSK9 inhibitors, and implemental gaps in the use of lipid-lowering therapies.
This online course covers different aspects of lipoprotein(a) (Lp(a)): the pathophysiology, its role in CVD risk and (novel) therapeutic options to reduce Lp(a) levels.
AHA 2020 Evolocumab additionally given to statins in ASCVD patients significantly reduced the risk of developing complex coronary disease that needs revascularization, including complex PCI or CABG.
Prof. Kastelein gives an introduction to the symposium about LDL-c lowering therapies with a specifiek focus on PSCK9 inhibition that was held during the virtual ESC 2020 congress.
Attainment of risk-based LDL-c goals in the ESC/EAS guidelines is low due to implementation gaps, but even with optimal statin use, combination therapy with PCSK9i is often needed to achieve 2019 LDL-c goals.
Prof. Bittner summarizes findings from post-hoc analyses of FOURIER and ODYSSEY OUTCOMES on the relationship between Lp(a) lowering by PCSK9 inhibition and CV risk.
EAS 2020 Inhibition of ANGPTL3 with evinacumab reduced LDL-c levels significantly in HoFH patients with little to no LDL receptor function.
EAS 2020 In a cohort of high-risk primary prevention individuals, 6-monthly injections with inclisiran reduced LDL-c and other atherogenic lipoproteins compared to placebo.
EAS 2020 Prof. Stein gives an overview of studies with the small binding protein targeting PCSK9, named LIB003.
EAS 2020 A subanalysis of the ORION-9 trial demonstrated that across subgroups of genotypes for heterozygous FH, inclisiran was equally effective in reducing LDL-c.
Prof. Stroes discusses the efficacy of PCSK9 inhibitors and which patients benefit most from LDL-c lowering (combination) therapies.
Prof. Mach explains the recommendations for pharmacological LDL-c lowering as described in the 2019 ESC/EAS guidelines for the management of dyslipidemia.